Business Wire

DEWA collaborates with several organisations to expand EV fast charging network

6.10.2025 15:51:00 CEST | Business Wire | Press release

Share

Dubai Electricity and Water Authority (DEWA) has signed agreement and contracts to expand the electric vehicle (EV) charging network across Dubai, as part of its EV Green Charger initiative, launched in 2014. DEWA signed the contracts and agreements with Emirates National Oil Company (ENOC), Dubai Taxi and Parkin company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006298551/en/

DEWA collaborates with several organisations to expand EV fast charging network (photo: AETOSWire)

“In collaboration with our partners from the government and private sectors, we are enhancing Dubai’s green mobility journey by building and developing an integrated infrastructure for charging electric vehicles. This contributes to reducing carbon emissions and achieving the goals of the Dubai Clean Energy Strategy 2050, the Dubai Net Zero Carbon Emissions Strategy 2050 and the Dubai Green Mobility Strategy. We continue to work with our partners across all sectors to establish the foundations of a sustainable green economy that meets the aspirations of our wise leadership and strengthens Dubai’s global competitiveness,” said HE Saeed Mohammed Al Tayer, MD & CEO of DEWA.

ENOC

DEWA has signed a contract with Enoc Group to expand the electric vehicle (EV) fast-charging network at ENOC service stations across Dubai. The initiative aims to enhance infrastructure to meet rising electric vehicle demand.

Dubai Taxi

DEWA and Dubai Taxi Company (DTC) signed a long-term strategic contract to deploy ultra-fast charging stations for electric vehicles within DTC’s fleet across the emirate. The project will see the rollout of 208 ultra-fast EV charge points over the duration of the contract, aligning with DTC’s fleet transformation road map and Dubai’s sustainability vision.

Parkin

DEWA and Parkin Company signed a strategic contract to transform Dubai’s public EV charging network, further strengthening the emirate’s global position as a leading hub for green and sustainable mobility. The first phase of the contract will see the installation of 100 EV chargers in key locations across Dubai, including residential communities, shopping malls, leisure destinations and public areas. A broader roll-out will follow in the near future to cover additional areas of the emirate. These chargers will offer greater flexibility, accelerating the transition to EV adoption.

Through its EV Green Charger initiative, DEWA provides more than 1,500 charging points across the emirate in collaboration with its partners from both the public and private sectors.

Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006298551/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye